Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can valsartan reduce the occurrence of atrial fibrillation in heart failure patients?

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 502–503 (2005)Cite this article

boxed-textMaggioni AP et al. (2005) Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149: 548–557

In HF patients, ARBs and ACE inhibitors should be used according to current guidelines, recognizing the increasing evidence that these drugs might exert some beneficial effects through a reduction in AF occurrence

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cha YM et al. (2004) Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 109: 2839–2843

    Article  Google Scholar 

  2. Nattel S (2002) New ideas about atrial fibrillation 50 years on. Nature 415: 219–226

    Article  CAS  Google Scholar 

  3. Klein HU and Goette A (2003) Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation? J Am Coll Cardiol 41: 2205–2206

    Article  Google Scholar 

  4. Allessie MA et al. (2001) Pathophysiology and prevention of atrial fibrillation. Circulation 103: 769–777

    Article  CAS  Google Scholar 

  5. Madrid AH et al. (2004) The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 27: 1405–1410

    Article  Google Scholar 

  6. McMurray J et al. (2005) Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45: 525–530

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Michael E DeBakey Veterans Affairs Medical Center and Assistant Professor of Medicine at the Winters Center for Heart Failure Research, Baylor College of Medicine,

    Anita Deswal & Douglas L Mann

  2. Winters Center for Heart Failure Research, Baylor College of Medicine, Houston, TX, USA

    Anita Deswal & Douglas L Mann

Authors
  1. Anita Deswal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Douglas L Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anita Deswal.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deswal, A., Mann, D. Can valsartan reduce the occurrence of atrial fibrillation in heart failure patients?. Nat Rev Cardiol 2, 502–503 (2005). https://doi.org/10.1038/ncpcardio0325

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0325

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing